Health economical model of smoking cessation with varenicline;Gesundheitsökonomisches Modell der Raucherentwähnung mitVareniclin

Suchtmedizin in Forschung und Praxis

Volumn 11, Issue 2, 2009, Pages 47-55

  Rasch, Andrej ^a   Greiner, Wolfgang ^a  

^a Dip Ok Andrej Rasch   (Germany)

Author keywords

Cost effectiveness; Economic model; Nicotine dependence; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; VARENICLINE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; ECONOMIC EVALUATION; GERMANY; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; NICOTINE REPLACEMENT THERAPY; SMOKING CESSATION; STROKE; TOBACCO DEPENDENCE;

EID: 67649878380     PISSN: 14375567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. American Heart Association (2005): Heart Disease and Stroke Statistics 2005 Update. DaIlas,Texas, American Heart Association
2. Arzneimittelkommission der deutschen Ärzteschaft (2004): Koronare Herzkrankheit. 1. Aufl. Arzneiverordnung in der Praxis, Therapieempfehlungen der Arzneimittelkommission der deutschen Arzteschaft
3. Ärztliches Zentrum für Qualität in der Medizin (2002): Leitlinienbericht KHK
4. Bolin K, Lindgren B, Willers S (2006): The Cost utility of bupropion in smoking cessation health pro ams: simulation model results for Sweden. Chest 129(3), 651-660
5. Duncan PW, Lai SM, KeighleyJ (2000): Defining post-stroke recovery: implicationsfor design and interpretation of drug trials. Neuropharmacology39 (5), 835-841
6. Epidemiologisches Krebsregister Saarland (2004): Epidemiologisches Krebsregister Saarland. http://www.krebsregister.saarland.de/publikationen/ PDF/Krebs-im-Saarland.pdf
7. Ezzati M, LopezAD (2003): Estimates of global mortality attributableto smoking in 2000. Lancet 362 (9387), 847-852
8. Fabel H, Konietzko N (2005): WeiBbuch Lunge 2005.3., neubearb. Aufi. FeenstraTL Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP (2005): Cost-effectiveness of face-to-face smoking cessation interventions:a dynamic modeling study.Value Health 8(3), 178-190
9. Fiscella K, Franks P (1 996):Cost-effectivenessofthetransdermal nicotine patch as an adjunctto physicians'smoking cessation counseling.JAMA 275(16), 1247-1 251
10. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM (2004): Advances in pharmacotherapyfortobacco dependence. ExpertOpin Emerg Drugs 9(1), 39-53
11. Gesellschaft der epidemiologischen Krebsregister in Deutschland eV (2006): Krebs in Deutschland, Haufigkeiten und Trends. 5. Uberarb., aktual.Ausg.
12. Gonzales D, Rennard Sl,Nides Metal.(2006a):Varenicline,analpha4beta2 nicotinicacetylcholine receptor partial agonist,vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1), 47-55
13. Gonzales DH, Rennard SI, Billing CB et al. (2006): A pooled analysis of varenicline, an á4â2 nicotinic receptor partial agonist versus bupropion and placebo for smoking cessation. 12th Society for Research on Nicotine and Tobacco Meeting. Abstract PA9 2
14. HannoveranerKonsensusGruppe (1999): Deutsche Empfehlungenzur gesundheitsokonomischen Evaluation -evidierte Fassung des Hannoveraner Konsens. Gesundh ökon Qual manag (4)
15. Hay JW, Sterling KL (2005): Cost effectiveness of treating low HDLcholesterol in the primary prevention ofcoronary heartdisease. Pharmacoeconomics23 (2), 133-141
16. Howard PA, Knight CJ, Baker CL (2007): Estimating the incidence and prevalence of smoking related morbidities using proxyvalues.Value Health 10(3),A101
17. John U, Hanke M (2001): Tobacco smoking attributable mortality in Germany. Gesundheitswesen 63(6), 363-369
18. Jorenby DE, Hays iT, Rigotti NA et al. (2006): Efficacy of varenicline, an alpha4beta2 nicotinicaceyl choline receptor partial agonist, vs placebo or sustained-release bupropionforsmoking cessation:a randomized controlled trial. JAMA 296(1), 56-63
19. KassenärztlicheBundesvereinigung (2006): Einheitlicher Bewertungsmaβstab. http//www.kbv.delebm2000plus/EBMGesamt.htm (Stand 4. Quartal 2006)
20. Kolominsky-Rabas PL,Sarti C, Heuschmann PUetaI.(1 998):Aprospective community-based study of stroke in Germany-the Erlangen Stroke Project (ESPr0): incidence and case fatality at 1,3, and 12 months. Stroke 29(12), 2501-2506
21. Krall EA, Garvey AJ, Garcia RI (2002): Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine TobRes4(1),95-100
22. Lader D, Goddard E (2005): Smoking Related Behaviour and Attitudes, 2004. Office of National Statistics
23. Lethbridge-Cejku M,VickerieJ (2005):Summaryhealth statisticsfor U.S. adults: National Health Interview Survey, 2003. National Center for Health Statistics. Vital Health Stat 10(225)
24. Löwel H (2006): Koronare Herzkrankheit und akuter Myokardinfarkt. (Heft 33). Robert Koch Institut. Gesundheitsberichterstattung des Bundes
25. Mannino DM, BuistAS, PettyTL EnrightPL, Redd SC (2003): Lungfunction and mortalityin the United States: data from the First National Health and Nutrition Examination Surveyfollowupstudy.Thorax58 (5), 388-393
26. National lnstituteforHealth and Clinical Excellence (2007): Varenicline forsmoking cessation. NlCEtechnologyappraisal guidance 123
27. Neubauer 5, Welte R, Beiche A et al. (2006): Mortality, morbidity and costs attributableto smoking in Germany: update and a 1 0-yearcom- parison.Tob Control 15(6), 464-471
28. NowakD, Dietrich ES, OberenderPetal. (2004): [Cost-of-illness Studyfor the Treatment of COPD in Germany]. Pneumologie 58(12), 837-844
29. Orme ME, Hogue SL, Kennedy LM, PaineAC, GodfreyC (2001): Development of the health and economic consequences of smoking interactive model.Tob Control 10(1), 55-6 1
30. Robert Koch-Institut (2004): Telefonischer Gesundheitssurvey des Robert Koch-Instituts zu chronischen Krankheiten und ihren Bedingungen
31. Robert Koch-lnstitut(2005): Auswertungsergebnisse: Herz- und Kreislauf-Krankheiten. httpi/www.rkLde/cln-O1 1/nn-254566/DE!Content/ GBE/A uswertungsergebnisse/nich tuebertrgbareKrankheiten HerzKreislaufKrankheiten/hkk- node.htmL-nnn=true
32. Robert Koch-Institut (2006): Dachdokumentation Krebs. http://www. rki.de/cln-006/nn-352008/DE/Content/GBE/DachdokKrebs/krebs-node.html-nnn= true
33. Ruff LK, Volmer T, Nowak D, Meyer A (2000): The economic impact of smoking in Germany. ur RespirJ 16(3), 385-390
34. Sachverständigenratfurdie Konzertierte Aktion im Gesundheitswesen (2001): Bedarfsgerechtigkeit und Wirtschaftlichkeit (Band Ill)
35. Schmidtmann I, Husmann G, Krtschil A, Seebauer G (2004): Krebs in Rheinland-Pfalz, lnzidenz und Mortalität im Jahr 2002
36. SilagyC, LancasterT, Stead L, MantD, FowlerG (2004): Nicotine replacementtherapyfor smoking cessation. Cochrane Database Syst Rev (3), CD0001 46
37. Single E, Rehm J, Robson L, Truong MV (2000): The relative risks and etiologicfractions ofdifferentcauses ofdeath and diseaseattributable toalcohol,tobaccoand illicitdrug use in Canada.CMAJ 162(12), 1669-1675
38. SpencerM, BriggsAH,Grossman RF, Rance L (2005): Developmentofan economic model to assess he cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23 (6), 619-637
39. Stang P,LydickE,SilbermanC,KempelA,Keating ET(2000):Theprevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 117(5 Suppl 2), 3545-3595
40. Statistisches Bundesamt Deutschland (2006): Leben in Deutschland - Mikrozensus 2005. http//www.destatis.de/presse!deutsch/pk12006/ mikrozensus2005- tabeiienanhang.pdf#search-%22%22 durchschnitt1iches%2OA!tei62Odes%2ORauchbeginns%22%22
41. Statistisches Bundesamt Deutschland (2006): Gesundheitsberichterstattung des Bundes.httpi/www.gbe-und.de/
42. TaylorTN, Davis PH,TornerJC et al. (1996): Lifetime cost ofstroke in the United States. Stroke 27(9), 1459-466
43. TengsTO, Lin TH (2003): A meta-analysis ofquality-of-life estimatesfor stroke. Pharma-oeconomics.21 (3), 191-200
44. Thun Mi, Apicella LF, Henley SJ (2000): Smoking vs other risk factors as the cause ofsmokingattributable deaths: confounding in the courtroom. JAMA 284(6), 706-712
45. Trippoli S,Vaiani M, Lucioni C, Messori A (2001 ):Qualityof lifeand utility in patientswith non-mall cell lung cancer.Quality-of-lifeStudyGroup ofthe Master2 Project in Pharmacoeconomics. Pharmacoeconomics 19 (8), 855-863
46. Tsevati, Kuntz KM,OravEJ etal.(2001 ):Cost-effectivenessofpravastatin therapyforsurvivorsofmyocardial infarction with averagecholesterol levels. Am Hearti 141 (5), 727-734
47. van Genugten ML, Hoogenveen RT, Mulderl etal. (2003): Future burden and costs of smoking- elated disease in the Netherlands: a dynamic modeling approach. Value Health 6(4), 494-499
48. WetterDW,Cofta-Gunn L Fouladi RTetal. (2004): Late relapse/sustained abstinenceamong formersmokers: a longitudinal study. Prey Med 39 (6), 1156-1163
49. WiesnerG,Grimmi, BittnerE (1 999a): [Incidenceof myocardial infarctin Germany: prevalence, incidencetrends, East-West comparison]. Gesundheitswesen 61 Spec No, 72-78
50. Wiesner G, Grimm J, Bittner E (1 999b): [Stroke: prevalence, incidence, trends, East-Westcomparion. Initial resultsofthe 1998 Federal Health Survey].Gesundheitswesen 61 Spec No,579-584
51. Woolacott NF,Jones L, ForbesCAetal. (2002):Theclinical effectiveness and costeffectiveness ofupropion and nicotine replacementtherapy forsmoking cessation: a systematic review and economic evaluation. Health Technol Assess 16(6)
52. World Health Organization (2001): WHOStatistical Information System (WHOSIS).http.J/www.who.int!whosis/en/
53. Worth H (2002): Leitlinie der deutschen Atemwegsliga und der Deutschen Gesellschaftfur PneumoogiezurDiagnostik und Therapievon Patienten mitchronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 56,704-738